Universe Pharmaceuticals (UPC) Current Deferred Revenue (2025)
Universe Pharmaceuticals (UPC) reported Current Deferred Revenue of $40.7 million for Q3 2025.
Universe Pharmaceuticals (UPC) Current Deferred Revenue (2025) Analysis & Trends
Universe Pharmaceuticals (UPC) has 1 years of Current Deferred Revenue data on file, last reported at $40.7 million in Q3 2025.
- For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $40.7 million; the trailing twelve-month figure through Sep 2025 stood at $40.7 million (changed N/A YoY), and the FY2025 full-year result was $40.7 million, changed N/A from the prior year.
- Current Deferred Revenue was little changed at $40.7 million in Q3 2025.
- In the past five years, Current Deferred Revenue ranged from a high of $40.7 million in Q3 2025 to a low of $40.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 40.71 Mn |